Key points are not available for this paper at this time.
Apandemic, according to the World Health Organization, is a widespread epidemic that affects a large number of people, spans across international boundaries, and occurs globally. Common initial symptoms of COVID-19 include fever, cough, fatigue, anorexia, and shortness of breath. However, the signs and symptoms can vary widely and affect different organ systems. Recent literature is starting to uncover the inuence of COVID-19 on the nervous system and its neuropsychiatric consequences. The ndings indicated a signicantly higher rate of psychiatric disorders among patients recovering from COVID-19. Within 90 days post-diagnosis, there was a 5.8% probability of being newly diagnosed with a psychiatric illness. Anxiety disorders, particularly adjustment disorder, generalized anxiety disorder (GAD), posttraumatic stress disorder (PTSD), and panic disorder, were the most frequently acquired diagnoses, with a 4.7% probability. Certainly, it is still debated whether psychosis is caused by COVID-19 or is a consequence of the drugs used for COVID-19 treatment (corticosteroids, antibiotics), internist conditions (hypoxemia, hydroelectrolyte imbalance), or related to stress due to long hospitalization or isolation. The ndings of this review, while still debatable, show that COVID-19 stimulates psychotic symptoms in three main ways: direct action of the virus, deregulation of the cytokine network, and stressors and uncertainty related to prognosis disease. However, gaps still exist in this area and should be a place for further research. Nonetheless, this review suggests that future research should rigorously investigate the incidence of psychiatric symptoms in individuals with coronavirus infections, and a prospective cohort of SARS-CoV-2 patients should be formed.
Sonowal et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: